TWI885720B - 眼科疾病之治療 - Google Patents

眼科疾病之治療 Download PDF

Info

Publication number
TWI885720B
TWI885720B TW113103154A TW113103154A TWI885720B TW I885720 B TWI885720 B TW I885720B TW 113103154 A TW113103154 A TW 113103154A TW 113103154 A TW113103154 A TW 113103154A TW I885720 B TWI885720 B TW I885720B
Authority
TW
Taiwan
Prior art keywords
weeks
ser
leu
val
thr
Prior art date
Application number
TW113103154A
Other languages
English (en)
Chinese (zh)
Other versions
TW202419464A (zh
Inventor
羅柏特 詹姆士 威克特
亞倫 奧斯本
嘉亞許瑞 沙尼
Original Assignee
美商建南德克公司
瑞士商赫孚孟拉羅股份公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商建南德克公司, 瑞士商赫孚孟拉羅股份公司 filed Critical 美商建南德克公司
Publication of TW202419464A publication Critical patent/TW202419464A/zh
Application granted granted Critical
Publication of TWI885720B publication Critical patent/TWI885720B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
TW113103154A 2018-02-06 2019-02-11 眼科疾病之治療 TWI885720B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862627103P 2018-02-06 2018-02-06
US62/627,103 2018-02-06
US201862729333P 2018-09-10 2018-09-10
US62/729,333 2018-09-10

Publications (2)

Publication Number Publication Date
TW202419464A TW202419464A (zh) 2024-05-16
TWI885720B true TWI885720B (zh) 2025-06-01

Family

ID=65352014

Family Applications (3)

Application Number Title Priority Date Filing Date
TW113103154A TWI885720B (zh) 2018-02-06 2019-02-11 眼科疾病之治療
TW108104518A TWI831764B (zh) 2018-02-06 2019-02-11 眼科疾病之治療
TW114116623A TW202535932A (zh) 2018-02-06 2019-02-11 眼科疾病之治療

Family Applications After (2)

Application Number Title Priority Date Filing Date
TW108104518A TWI831764B (zh) 2018-02-06 2019-02-11 眼科疾病之治療
TW114116623A TW202535932A (zh) 2018-02-06 2019-02-11 眼科疾病之治療

Country Status (12)

Country Link
US (2) US20210139576A1 (enExample)
EP (1) EP3749359A1 (enExample)
JP (5) JP7005772B2 (enExample)
KR (3) KR20240093772A (enExample)
CN (4) CN111699004A (enExample)
AU (3) AU2019219004B2 (enExample)
CA (1) CA3088355A1 (enExample)
IL (1) IL276383B2 (enExample)
MX (1) MX2020007527A (enExample)
SG (1) SG11202006712XA (enExample)
TW (3) TWI885720B (enExample)
WO (1) WO2019154776A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2017117464A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
BR112020015074A2 (pt) 2018-01-26 2020-12-08 The Regents Of The University Of California Métodos e composições para tratamento de transtornos angiogênicos com uso de agentes anti-vegf
BR112020017872A2 (pt) 2018-03-02 2020-12-22 Kodiak Sciences Inc. Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos
TWI881273B (zh) * 2019-08-06 2025-04-21 美商建南德克公司 眼科疾病之個人化治療
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CA3168512A1 (en) 2019-11-25 2021-06-03 Napoleone Ferrara Long-acting vegf inhibitors for intraocular neovascularization
AU2021335509B2 (en) 2020-09-04 2025-11-13 F. Hoffmann-La Roche Ag Antibody that binds to VEGF-A and ANG2 and methods of use
TW202221027A (zh) * 2020-09-17 2022-06-01 大陸商江蘇恆瑞醫藥股份有限公司 特異性結合ｖｅｇｆ和ａｎｇ－２的雙特異性抗原結合分子
JP2024512701A (ja) * 2021-03-30 2024-03-19 アブプロ コーポレーション 抗ａｎｇ２×ｖｅｇｆ多重特異性抗体を用いて脈絡膜新生血管形成を治療するための方法
WO2022231930A1 (en) 2021-04-26 2022-11-03 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
EP4392038A4 (en) * 2021-08-23 2025-06-11 Avirmax Biopharma Inc. COMPOSITIONS AND METHODS FOR TRANSGENE EXPRESSION
CN117100845A (zh) * 2022-10-24 2023-11-24 景泽生物医药(合肥)股份有限公司 重组人奥克纤溶酶在制备治疗脉络膜血管疾病药物中的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI506036B (zh) * 2012-07-13 2015-11-01 羅齊克雷雅公司 雙特異性抗－ｖｅｇｆ／抗－ａｎｇ－２抗體及其治療眼部血管疾病之用途

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
BRPI9809387B8 (pt) 1997-04-07 2021-05-25 Genentech Inc anticorpo humanizado anti-fator de crescimento endotelial vascular humano e composição que o compreende
ES2246069T3 (es) 1997-05-02 2006-02-01 Genentech, Inc. Procedimiento de preparacion de anticuerpos multiespecificos que tienen componentes comunes y multimericos.
US10011858B2 (en) 2005-03-31 2018-07-03 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
US8871912B2 (en) 2006-03-24 2014-10-28 Merck Patent Gmbh Engineered heterodimeric protein domains
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
SI2235064T1 (sl) 2008-01-07 2016-04-29 Amgen Inc. Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
CA2759233C (en) 2009-04-27 2019-07-16 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
CN103124743A (zh) 2009-12-29 2013-05-29 新兴产品开发西雅图有限公司 Ron结合构建物及其使用方法
TWI426920B (zh) 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
EP2569337A1 (en) 2010-05-14 2013-03-20 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
CA2815266C (en) 2010-11-05 2023-09-05 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
EP3763379A1 (en) * 2011-01-13 2021-01-13 Regeneron Pharmaceuticals, Inc. Use of a vegf antagonist to treat angiogenic eye disorders
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
PL2794905T3 (pl) 2011-12-20 2020-11-02 Medimmune, Llc Zmodyfikowane polipeptydy dla rusztowań przeciwciał dwuswoistych
RS59263B1 (sr) 2012-04-20 2019-10-31 Merus Nv Postupci i sredstva za proizvodnju heterodimernih ig-sličnih molekula
JP6336448B2 (ja) * 2012-08-21 2018-06-06 オプコ ファーマシューティカルズ、エルエルシー リポソーム製剤
ES2871383T3 (es) 2013-04-29 2021-10-28 Hoffmann La Roche Anticuerpos asimétricos modificados que se unen al receptor de Fc y procedimientos de uso
KR20150063728A (ko) 2013-12-02 2015-06-10 삼성전자주식회사 항 VEGF-C/항 Ang2 이중 특이 항체
TWI806150B (zh) * 2014-11-07 2023-06-21 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
US20160144025A1 (en) * 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
CA2970315C (en) * 2014-12-11 2023-08-22 Bayer Healthcare Llc Use of anti-vegf agents to treat lesions in macular degeneration patients
AR103477A1 (es) * 2015-01-28 2017-05-10 Lilly Co Eli Compuestos de vegfa / ang2
EP3454903A4 (en) 2016-05-13 2020-08-19 Askgene Pharma, Inc. NEW DOUBLE ANTAGONISTS OF ANGIOPOIETIN 2, VEGF
AR108800A1 (es) * 2016-06-17 2018-09-26 Genentech Inc Purificación de anticuerpos multiespecíficos

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI506036B (zh) * 2012-07-13 2015-11-01 羅齊克雷雅公司 雙特異性抗－ｖｅｇｆ／抗－ａｎｇ－２抗體及其治療眼部血管疾病之用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
期刊 Chakravarthy, Usha et al. Phase I Trial of Anti-Vascular Endothelial Growth Factor/Antiangiopoietin 2 Bispecific Antibody RG7716 for Neovascular Age-Related Macular Degeneration. Ophthalmology Retina, VOL 1, NO 6, 2017/05/23, page 474-485. *

Also Published As

Publication number Publication date
TW202419464A (zh) 2024-05-16
KR20240093772A (ko) 2024-06-24
CN119770646A (zh) 2025-04-08
IL276383B1 (en) 2023-09-01
AU2019219004B2 (en) 2025-06-05
IL276383B2 (en) 2024-01-01
JP7646727B2 (ja) 2025-03-17
JP7273204B2 (ja) 2023-05-12
WO2019154776A1 (en) 2019-08-15
SG11202006712XA (en) 2020-08-28
IL276383A (en) 2020-09-30
KR20200119274A (ko) 2020-10-19
CN119909169A (zh) 2025-05-02
US20210139576A1 (en) 2021-05-13
AU2025220842A1 (en) 2025-09-11
TW202000700A (zh) 2020-01-01
JP7005772B2 (ja) 2022-02-10
JP2023099094A (ja) 2023-07-11
MX2020007527A (es) 2020-09-09
TWI831764B (zh) 2024-02-11
JP2022046738A (ja) 2022-03-23
KR20250166355A (ko) 2025-11-27
JP2021506947A (ja) 2021-02-22
CN119733046A (zh) 2025-04-01
JP2025084976A (ja) 2025-06-03
AU2025220841A1 (en) 2025-09-11
US20230416353A1 (en) 2023-12-28
EP3749359A1 (en) 2020-12-16
CN111699004A (zh) 2020-09-22
CA3088355A1 (en) 2019-08-15
JP2025084977A (ja) 2025-06-03
AU2019219004A1 (en) 2020-07-16
TW202535932A (zh) 2025-09-16

Similar Documents

Publication Publication Date Title
JP7646727B2 (ja) 眼科疾患の処置
TWI881273B (zh) 眼科疾病之個人化治療
HK40034720A (zh) 眼科疾病的治疗
HK40065038A (en) Personalized treatment of ophthalmologic diseases
HK40065038B (zh) 眼科疾病的个性化治疗